Roche Venture Fund returned to help SutroVax, a developer of vaccines for a range of deadly infectious diseases, push its overall funding past $280m.
US-based vaccine developer SutroVax received $110m yesterday in a series D round featuring pharmaceutical firm Roche, which invested through corporate venturing subsidiary Roche Venture Fund.
RA Capital Management and Janus Henderson Investors co-led the round, which included Pivotal BioVenture Partners, the healthcare technology fund backed by property developer Nan Fung, as well as TPG Growth, Abingworth, Longitude Capital, Frazier Healthcare Partners, Medicxi, CTI Life Sciences and Foresite Capital.
Spun off from biopharmaceutical company Sutro Biopharma in 2014, SutroVax is working…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
